Conforma Therapeutics Corporation Initiates Two Phase I Studies Of HSP90 Inhibitor CNF1010 In Patients With Solid Tumors And Chronic Myelogenous Leukemia
10/19/2005 5:11:20 PM
Conforma Therapeutics Corporation today announced that it has initiated two Phase I human clinical trials of CNF1010, a small molecule inhibitor of heat shock protein 90 (HSP90). One trial is enrolling cancer patients with advanced solid tumors, while the other trial is being conducted with cancer patients suffering from Chronic Myelogenous Leukemia (CML). CNF1010 contains a new proprietary form of the geldanamycin derivative 17-AAG, in a novel, commercially viable formulation developed by Conforma.
comments powered by